The FDA could make it harder for developers of CAR-T therapies to bring them to market by requiring full randomised controlled trials.
Tenaya targets $60M offering after heart disease pipeline updates
Tenaya Therapeutics, a company focused on developing gene therapies for heart conditions, made a series of announcements on Thursday. The biotech said the FDA has


